Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €8.36 EUR
Change Today -0.014 / -0.17%
Volume 230.0
AFF On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 3:38 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

affymetrix inc (AFF) Snapshot

Open
€8.42
Previous Close
€8.37
Day High
€8.75
Day Low
€8.34
52 Week High
03/19/15 - €12.38
52 Week Low
10/15/14 - €5.45
Market Cap
666.9M
Average Volume 10 Days
168.0
EPS TTM
--
Shares Outstanding
79.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AFFYMETRIX INC (AFF)

affymetrix inc (AFF) Related Businessweek News

No Related Businessweek News Found

affymetrix inc (AFF) Details

Affymetrix, Inc. provides life science products and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein, and cell level primarily in the United States, Europe, Latin America, and Asia. The company operates in two segments, Affymetrix Core and eBioscience. The Affymetrix Core segment engages in the development, manufacture, and commercialization of systems for genetic analysis in the life sciences and diagnostic industry. This segment develops and markets GeneChip gene expression products and services; genotyping product line; products with clinical diagnostic and research applications, such as the CytoScan and OncoScan products; GeneTitan instrument system that runs genotyping and gene expression array plates; and QuantiGene line of singleplex and multiplex assays to serve customers in the research and translational medicine markets. It also offers life science reagents, such as ExoSAP-IT for a reagent for the clean-up of polymerase chain reaction, and HotStart-IT reagents to inhibit primer dimer formation; enzymes; purification kits; and biochemicals for life science researchers and other biological and health care manufacturers. The eBioscience segment is involved in the development, manufacturing, marketing, and distribution of research products in the areas of flow cytometry, immunoassays, microscopic imaging, and other protein-based analyses. This segment offers a portfolio of antibodies and reagents, as well as a range of the QuantiGene and Procarta Plex assays for low to mid-plex experiments. The company sells its products directly and through third party distributors to genomic research centers, academic institutions, government, and private laboratories, as well as pharmaceutical, diagnostic, and biotechnology companies. It has collaboration agreement with Cytox Ltd. The company was founded in 1991 and is headquartered in Santa Clara, California.

1,200 Employees
Last Reported Date: 07/30/15
Founded in 1991

affymetrix inc (AFF) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $549.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $349.8K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $399.8K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $349.8K
Compensation as of Fiscal Year 2014.

affymetrix inc (AFF) Key Developments

Affymetrix Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Raises Financial Guidance for the Full Year of 2015

Affymetrix Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenue of $88,966,000 against $85,432,000 a year ago. Profit from operations was $8,526,000 against loss from operations of $304,000 a year ago. Profit before income taxes was $7,330,000 against loss before income taxes of $509,000 a year ago. Net profit was $7,006,000 or $0.08 diluted per share against net loss of $911,000 or $0.01 basic and diluted per share a year ago. Non-GAAP net income was $10,454,000 or $0.12 diluted per share against $5,157,000 or $0.07 basic and diluted per share a year ago. EBITDA was $14,138,000 compared to $10,676,000 for the same period a year ago. Adjusted EBITDA was $17,134,000 compared to $13,864,000 for the same period a year ago. In the second quarter, the company generated solid cash flow, around about $10 million from operating activities. For the six months, the company reported total revenue of $177,684,000 against $168,403,000 a year ago. Profit from operations was $15,810,000 against loss from operations of $9,045,000 a year ago. Profit before income taxes was $12,459,000 against loss before income taxes of $10,711,000 a year ago. Net profit was $11,392,000 or $0.14 diluted per share against $11,385,000 or $0.16 basic and diluted per share a year ago. Non-GAAP net income was $18,338,000 or $0.21 diluted per share against $7,061,000 or $0.10 basic and diluted per share a year ago. EBITDA was $26,283,000 compared to $13,813,000 for the same period a year ago. Adjusted EBITDA was $34,265,000 compared to $26,780,000 for the same period a year ago. The company reiterates guidance for full year revenue growth in the mid-single digit range on a constant currency basis, increased gross margin, and raising adjusted EBITDA guidance from a range of 16-18% to 17-19% for 2015. The company increase 2015 full year guidance for non-GAAP gross margin from 61% to 63%.

Cytox Partners with Affymetrix to Collaborate on Developing and Commercializing Blood-Based Genetic Assay for Research in Diagnosis and Prognosis of Alzheimer's Disease and Mild Cognitive Impairment

Cytox Ltd. and Affymetrix Inc. have formed a strategic partnership to collaborate on developing and commercializing a blood-based genetic assay for research in diagnosis and prognosis of Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI). The transaction will allow Affymetrix to extend its offering into the Alzheimer's disease (AD) and dementia research market with a new application.

Affymetrix, Inc., BioRealm, LLC, and RUCDR Infinite Biologics Announce Broad Strategic Alliance

Affymetrix Inc., BioRealm, LLC, and RUCDR Infinite Biologics announced a broad strategic alliance. This alliance will leverage BioRealm's SmokeScreen® platform to genotype the National Institute on Drug Abuse (NIDA) biorepository of more than 50,000 samples, collected from human subjects studied in NIDA-funded research. NIDA preserves these samples in a biorepository at RUCDR Infinite Biologics, on the campus of Rutgers University. The biorepository is maintained by RUCDR Infinite Biologics and in part through collaboration with the BioProcessing Solutions Alliance which was created by RUDCR Infinite Biologics and BioStorage Technologies. Once the genetic information contained in these samples is made available to researchers, it will be extremely valuable for studying the link between genetic variations and addiction. Detailed genetic information might, for example, be used by researchers exploring how genetics influences patients’ individual responses to treatment approaches. To date, the genetic information contained in these samples has been focused on specific targets and not collectively analyzed. This strategic alliance makes it possible, for the first time ever, to cost-efficiently analyze this valuable information. The genetic information will be obtained by using BioRealm’s SmokeScreen® array, developed in conjunction with NIDA’s Genetics Consortium and Affymetrix. SmokeScreen® array is a genome-wide array with research-driven focus on more than 1,000 addiction-related genes.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AFF:GR €8.36 EUR -0.014

AFF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Fluidigm Corp $11.70 USD +0.32
Foundation Medicine Inc $23.80 USD +0.89
Luminex Corp $18.46 USD -0.07
Sequenom Inc $2.23 USD +0.09
Takara Bio Inc ¥1,196 JPY +48.00
View Industry Companies
 

Industry Analysis

AFF

Industry Average

Valuation AFF Industry Range
Price/Earnings 43.0x
Price/Sales 2.1x
Price/Book 2.3x
Price/Cash Flow 39.9x
TEV/Sales 1.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AFFYMETRIX INC, please visit www.affymetrix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.